SITE REVISION NOTICE: Main site is currently updating. You are viewing the exclusive early-access portal for new programs and tools launching soon.
FOR HEALTHCARE AND LIFE SCIENCE COMPANIES READY TO GROW
Know where your company stands, what to fix first, and what investors will see.
100-Point Diagnostic Engine : Institutional Due Diligence Standard
Scale Capital
Shift Channel
Verify Data
Cap Burn Rate
FROM SCORE TO SCALE
A structured four-phase transition from initial diagnostic benchmark to hands-on embedded commercial leadership. Clear decision gates replace guesswork.
PHASE 01
SCORE
Participate in the live executive webinar and complete your complimentary diagnostic to establish an empirical readiness baseline.
DELIVERABLE: Baseline Readiness Index
PHASE 02
REVIEW
Undergo an intensive diagnostic audit where senior leadership analyzes vulnerability areas, commercialization bottlenecks, and regulatory blindspots.
DELIVERABLE: Executive Gap Audit
PHASE 03
PLAN
Construct a commercialization roadmap embedded with Go, Pivot, Pause, and Stop decision gates to safeguard capital deployment.
DELIVERABLE: Decision Gate Roadmap
PHASE 04
SCALE
Deploy direct, hands-on advisory with Gregg A Jackson as a fractional commercialization partner to orchestrate market entry and growth.
DELIVERABLE: Fractional CCO Leadership
2-3 minute executive diagnostic • Instant preliminary benchmark • Zero software installation
WHO THIS IS FOR
The SCORE2SCALE™ framework is reserved for executive operators, portfolio managers and institutional investors confronting critical commercialization hurdles in high-stakes healthcare environments.
PROFILE: QUALIFIED CRITERIA
BUILT FOR
Designed for funded healthcare ventures where investibility and commercial friction directly caps valuation, investor confidence, and market trajectory.
- Funded, revenue-generating healthcare & medtech enterprises
- Leadership teams facing commercialization and scale roadblocks
- PE/VC portfolio partners aiming to derisk follow-on valuations
- Founders ready to enforce disciplined go/no-go operational decisions
STATUS: PRIORITY ACCESS - Rigorous evaluation designed to protect capital and accelerate viable growth vectors.
PROFILE: EXCLUSION CRITERIA
NOT BUILT FOR
Not suitable for early theoretical exploration or teams unable to commit executive resources toward commercial governance.
- Pre-revenue, pre-seed concepts seeking basic scientific validation
- Organizations seeking passive checklists without decisive action
- Teams unwilling to audit go-to-market assumptions or reallocate budget
- Projects lacking dedicated executive authority to execute structural shifts
STATUS: RESTRICTED ENTRY - Consultative resources are strictly reserved for high-conviction, execution-ready portfolios.
GREGG A. JACKSON
Managing Partner & Strategic Operator
Lead Healthcare Syndicate Investor
Direct Capital Access: Active syndication across 8 premier healthcare angel networks, investment funds and micro-VC funds. Focused on clinical validation, non-dilutive scaling, and tier-one strategic acquirer positioning.
EXECUTIVE TRACK RECORD & DUAL AUTHORITY
THE OPERATOR AND INVESTOR
Most strategic advisors understand either clinical governance or balance sheet engineering. Gregg A. Jackson operates at the exact intersection of both. Over a 25-year institutional career, he has commanded high-stakes medtech commercialization from internal boardrooms to angel syndicate investment committees.
INSTITUTIONAL RIGOR: ABBOTT, J&J, BOSTON SCIENTIFIC, MEDTRONIC & 4 EXITS
Gregg's operational pedigree stems from steering category-leading organizations including Abbott, J&J, Boston Scientific and Medtronic. Having built, commercialized, and guided 4 technology platforms to full enterprise liquidity, his strategic recommendations are not theoretical models—they are the direct byproduct of live capital deployment and boardroom accountability.
4 Proven Commercial Exits in Clinical Equipment, Diagnostics & Healthcare IT
Executive Strategic Leadership at top tier and mid-tier companies
Active Investment Committee & Screening Lead across 8 Top Healthcare Angel Groups
Architect of the SCORE2SCALE™ Diagnostic Framework for Growth-Stage Founders
THURSDAY, NOVEMBER 12, 2026, 12:00 PM ET.
Score Before You Scale:
The 7 commercialization Gaps Investors Spot First
30 minutes, action packed. You leave with a plan, not just notes
Your top commercialization gaps, scored across the 7 Keys
A GO, PIVOT, PAUSE or STOP call for your next 90 days
Lessons from 4 exits and $6B+ in launches, including what went wrong
Free the moment you register: the Pre-Commercialization & Investability Workbook, plus the online SCORE2SCALE™ assessment that gives you your score. Attendees also get the Executive Guide to Commercialization.
Format: 30 minutes plus 15 minutes of Q&A, on Zoom
QUALIFIED EXECUTIVES ONLY
READY TO GO FURTHER?
Have your SCORE2SCALE™ score and ready to act? Only qualified applicants see Gregg's calendar.
For companies with $10M+ in revenue, investors and family offices. Startups can book a paid Executive Review.
GREGG A. JACKSON
Commercialization Strategy, Investor Readiness & Executive Advisory for life science founders, medical device and biotechnology CEOs, and institutional investment committees navigating commercial scale.
NAVIGATION & RESOURCES
© 2026 Gregg A. Jackson. All rights reserved. SCORE2SCALE™ is a proprietary strategic framework.
STRICTLY CONFIDENTIAL & PROPRIETARY. Advisory consultations and analytical scorings are provided under mutual non-disclosure. Decision gate models do not constitute formal broker-dealer underwriting or securities advice.